{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T18:01:43Z","timestamp":1784570503612,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA274321"],"award-info":[{"award-number":["U54CA274321"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cisplatin remains the standard systemic therapy for the definitive treatment of head and neck squamous cell carcinoma (HNSCC), however, resistance to cisplatin continues to be a major barrier to effective treatment, particularly in tumors with NRF2 hyperactivation. Recent studies identify secreted phosphoprotein 1 (SPP1\/osteopontin) as a key NRF2 target frequently overexpressed in cancers, where it drives aggressive tumor behavior, metastasis, chemoresistance, and, in some cases, immune suppression. Our recent data highlight SPP1 as one of the top 10 NRF2-upregulated genes in cisplatin-resistant HNSCC. However, its specific role in therapy resistance and metastasis in HNSCC remains unclear. Here, we investigate whether targeting SPP1 can suppress tumor aggressiveness and improve cisplatin response in HNSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using established human HNSCC cell lines and mouse models, we utilized conventional western blotting, cell invasion, functional proteomics and high resolution spatial transcriptomics to examine the role of SPP1 in driving tumor progression and metastasis in therapy-resistant HNSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Targeted suppression of SPP1 improved cisplatin sensitivity, inhibited tumor invasion and metastasis both in vitro and in vivo and reduced expression of several metastatic signaling proteins in NRF2-hyperactivated HNSCC. Proteomic analysis revealed that silencing SPP1 led to dysregulation of critical oncogenic and metastatic signaling pathways, including MAPK, AKT\/mTOR, FAK, and PAK1. Spatial transcriptomic analysis uncovered a potential mechanistic interaction between SPP1, integrins and CD44 receptors in both primary and metastatic HNSCC. Spatial annotation and enrichment analyses using HALLMARK revealed gene set signatures of interferon and EMT present in cell clusters with SPP1 expression in both the primary tumor and lung metastases. Finally, increased expression of SPP1 was found to be poor prognostic factor and significantly correlated with\n                      <jats:italic>NFE2L2\/KEAP1<\/jats:italic>\n                      mutational status and higher tumor grade in HNSCC patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Targeting dysregulated SPP1 improved cisplatin sensitivity and suppressed tumor invasion and metastasis in NRF2-hyperactivated HNSCC, underscoring the therapeutic potential of SPP1 inhibitors to improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08292-x","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:14:42Z","timestamp":1779470082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted suppression of SPP1 inhibits tumor invasion and metastasis in NRF2 hyperactivated cisplatin resistant HNSCC"],"prefix":"10.1186","volume":"24","author":[{"given":"Mutsuki","family":"Kawabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena I.","family":"Gomez-Bolanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia D.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-You","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arisa Nishikawa","family":"Kaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell J.","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad C.","family":"Sandulache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humam","family":"Kadara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A.","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"8292_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay MEJ, Siegel RL, Soerjomataram I, Jemal A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"8292_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"8292_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","volume":"382","author":"LQM Chow","year":"2020","unstructured":"Chow LQM. Head and Neck Cancer. New Engl J Med. 2020;382(1):60\u201372. https:\/\/doi.org\/10.1056\/NEJMra1715715.","journal-title":"New Engl J Med"},{"issue":"2","key":"8292_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/medsci11020042","volume":"11","author":"A Barsouk","year":"2023","unstructured":"Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A, Epidemiology. Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci (Basel). 2023;11(2):42. https:\/\/doi.org\/10.3390\/medsci11020042.","journal-title":"Med Sci (Basel)"},{"key":"8292_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.21733","author":"LA Dunn","year":"2025","unstructured":"Dunn LA, Ho AL, Pfister DG, Head, Cancer N, Review A. JAMA. 2025. https:\/\/doi.org\/10.1001\/jama.2025.21733.","journal-title":"JAMA"},{"issue":"19","key":"8292_CR6","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375(19):1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252. (this is become #6).","journal-title":"N Engl J Med"},{"key":"8292_CR7","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G Jr, Psyrri A, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7.","journal-title":"Lancet"},{"key":"8292_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri R, Haddad RI, Tao Y, Le Tourneau C, Lee NY, Westra W, et al. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. N Engl J Med. 2025;393:37\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2415434.","journal-title":"N Engl J Med"},{"issue":"1","key":"8292_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12032-023-02237-w","volume":"41","author":"R Fu","year":"2023","unstructured":"Fu R, Zhao B, Chen M, Fu X, Zhang Q, Cui Y, et al. Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy. Med Oncol. 2023;41(1):9. https:\/\/doi.org\/10.1007\/s12032-023-02237-w.","journal-title":"Med Oncol"},{"issue":"7","key":"8292_CR10","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-22-2747","volume":"29","author":"AA Osman","year":"2023","unstructured":"Osman AA, Arslan E, Bartels M, Michikawa C, Lindemann A, Tomczak K, et al. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2023;29(7):1344\u201359. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2747.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"8292_CR11","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1038\/s41416-023-02253-7","volume":"128","author":"W Yu","year":"2023","unstructured":"Yu W, Chen Y, Putluri N, Osman A, Coarfa C, Putluri V, et al. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. Br J Cancer. 2023;128(11):2013\u201324. https:\/\/doi.org\/10.1038\/s41416-023-02253-7.","journal-title":"Br J Cancer"},{"key":"8292_CR12","doi-asserted-by":"publisher","unstructured":"Yi X, Luo L, Zhu Y, Deng H, Liao H, Shen Y, Zheng Y. SPP1 facilitates cell migration and invasion by targeting COL11A1 in lung adenocarcinoma. Cancer Cell Int. 2022;22(234). https:\/\/doi.org\/10.1186\/s12935-022-02749-x.","DOI":"10.1186\/s12935-022-02749-x"},{"key":"8292_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/ijc.23204","volume":"122","author":"M Mirza","year":"2008","unstructured":"Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF. Osteopontin-c is a selective marker of breast cancer. Int J Cancer. 2008;122:889\u201397. https:\/\/doi.org\/10.1002\/ijc.23204.","journal-title":"Int J Cancer"},{"key":"8292_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/jnci\/94.7.513","volume":"94","author":"D Agrawal","year":"2002","unstructured":"Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002;94:513\u201321. https:\/\/doi.org\/10.1093\/jnci\/94.7.513.","journal-title":"J Natl Cancer Inst"},{"key":"8292_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/biomedicines11010197","volume":"11","author":"C Hao","year":"2023","unstructured":"Hao C, Lane J, Jiang WG. Osteopontin and Cancer: Insights into Its Role in Drug Resistance. Biomedicines. 2023;11:197. https:\/\/doi.org\/10.3390\/biomedicines11010197.","journal-title":"Biomedicines"},{"key":"8292_CR16","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1186\/s12967-024-06018-5","volume":"22","author":"J Zhang","year":"2024","unstructured":"Zhang J, Peng Q, Fan J, Liu F, Chen H, Bi X, Yuan S, et al. Single-cell and spatial transcriptomics reveal SPP1-CD44 signaling drives primary resistance to immune checkpoint inhibitors in RCC. J Transl Med. 2024;22:1157. https:\/\/doi.org\/10.1186\/s12967-024-06018-5.","journal-title":"J Transl Med"},{"key":"8292_CR17","doi-asserted-by":"publisher","unstructured":"Yan Z, Hu X, Tang B, Deng F. Role of osteopontin in cancer development and treatment. Heliyon. 2023;9(10). https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21055.","DOI":"10.1016\/j.heliyon.2023.e21055"},{"issue":"7","key":"8292_CR18","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/biomedicines1207152","volume":"12","author":"VK Panda","year":"2024","unstructured":"Panda VK, Mishra B, Nath AN, Butti R, Yadav AS, Malhotra D, et al. Osteopontin: A Key Multifaceted Regulator in Tumor Progression and Immunomodulation. Biomedicines. 2024;12(7):1527. https:\/\/doi.org\/10.3390\/biomedicines1207152.","journal-title":"Biomedicines"},{"key":"8292_CR19","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/cancers12061670","volume":"12","author":"W Yu","year":"2020","unstructured":"Yu W, Chen Y, Putluri N, Coarfa C, Robertson MJ, Putluri V, et al. Acquisition of cisplatin resistance shifts head and neck squamous cell carcinoma metabolism toward neutralization of oxidative stress. Cancers. 2020;12:1670. https:\/\/doi.org\/10.3390\/cancers12061670.","journal-title":"Cancers"},{"key":"8292_CR20","doi-asserted-by":"publisher","first-page":"7248","DOI":"10.1158\/1078-0432.CCR-11-0690","volume":"17","author":"M Zhao","year":"2011","unstructured":"Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res. 2011;17:7248\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0690.","journal-title":"Clin Cancer Res"},{"key":"8292_CR21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/1535-7163.MCT-14-0735-T","volume":"14","author":"AA Osman","year":"2015","unstructured":"Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, et al. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol Cancer Ther. 2015;14:608\u201319. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0735-T.","journal-title":"Mol Cancer Ther"},{"key":"8292_CR22","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/lary.23846","volume":"123","author":"T-X Xie","year":"2013","unstructured":"Xie T-X, Zhou G, Zhao M, Sano D, Jasser SA, Brennan RG, Jeffrey N, Myers. Serine Substitution of Proline at Codon 151 of TP53 Confers Gain of Function Activity Leading to Anoikis Resistance and Tumor Progression of Head and Neck Cancer Cells. Laryngoscope. 2013;123:1416\u201323. https:\/\/doi.org\/10.1002\/lary.23846.","journal-title":"Laryngoscope"},{"issue":"8","key":"8292_CR23","doi-asserted-by":"publisher","first-page":"e004752","DOI":"10.1136\/jitc-2022-004752","volume":"10","author":"KM Ahmed","year":"2022","unstructured":"Ahmed KM, Veeramachaneni R, Deng D, Putluri N, Putluri V, Cardenas MF, Wheeler DA, et al. Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response. J Immunother Cancer. 2022;10(8):e004752. https:\/\/doi.org\/10.1136\/jitc-2022-004752.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"8292_CR24","doi-asserted-by":"publisher","first-page":"e0321631","DOI":"10.1371\/journal.pone.0321631","volume":"20","author":"MJ Frederick","year":"2025","unstructured":"Frederick MJ, Perez-Bello D, Yadollahi P, Castro P, Osman RA, Essien F, et al. Reliable RNA-seq analysis from FFPE specimens as a means to accelerate cancer-related health disparities research. PLoS ONE. 2025;20(4):e0321631. https:\/\/doi.org\/10.1371\/journal.pone.0321631.","journal-title":"PLoS ONE"},{"issue":"24","key":"8292_CR25","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1158\/0008-5472.CAN-18-3560","volume":"79","author":"A Jim\u00e9nez-S\u00e1nchez","year":"2019","unstructured":"Jim\u00e9nez-S\u00e1nchez A, Cast O, Miller ML. Comprehensive Benchmarking and Integration of Tumor Microenvironment Cell Estimation Methods. Cancer Res. 2019;79(24):6238\u201346. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3560.","journal-title":"Cancer Res"},{"key":"8292_CR26","doi-asserted-by":"publisher","unstructured":"Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2:798\u2013811. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0112.","DOI":"10.1158\/2159-8290.CD-12-0112"},{"key":"8292_CR27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41592-022-01728-4","volume":"20","author":"Z Cang","year":"2023","unstructured":"Cang Z, Zhao Y, Almet AA, Stabell A, Ramos R, Plikus MV, et al. Screening cell\u2013cell communication in spatial transcriptomics via collective optimal transport. Nat Methods. 2023;20:218\u201328. https:\/\/doi.org\/10.1038\/s41592-022-01728-4.","journal-title":"Nat Methods"},{"key":"8292_CR28","doi-asserted-by":"publisher","unstructured":"Zhang D, Schroeder A, Yan H, et al. Inferring super-resolution tissue architecture by integrating spatial transcriptomics with histology. Nature Biotechnol. 2024;42(9):1372\u20131377. https:\/\/doi.org\/10.1038\/s41587-023-02019-9.","DOI":"10.1038\/s41587-023-02019-9"},{"key":"8292_CR29","doi-asserted-by":"publisher","first-page":"646390","DOI":"10.3389\/fcell.2021.646390","volume":"9","author":"H Tang","year":"2021","unstructured":"Tang H, Chen J, Han X, Feng Y, Wang F. Upregulation of SPP1 Is a Marker for Poor Lung Cancer Prognosis and Contributes to Cancer Progression and Cisplatin Resistance. Front Cell Dev Biol. 2021;9:646390. https:\/\/doi.org\/10.3389\/fcell.2021.646390.","journal-title":"Front Cell Dev Biol"},{"key":"8292_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41419-022-04806-9","volume":"13","author":"Q Wu","year":"2022","unstructured":"Wu Q, Li L, Miao C, Hasnat M, Sun L, Jiang Z, Zhang L. Osteopontin promotes hepatocellular carcinoma progression through inducing JAK2\/STAT3\/NOX1-mediated ROS production. Cell Death Dis. 2022;13:341. https:\/\/doi.org\/10.1038\/s41419-022-04806-9.","journal-title":"Cell Death Dis"},{"issue":"21","key":"8292_CR31","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1158\/0008-5472.CAN-25-1486","volume":"85","author":"Y Gu","year":"2025","unstructured":"Gu Y, Muller WJ. The Multifaceted Role of Osteopontin in Modulating the Tumor Microenvironment. Cancer Res. 2025;85(21):4049\u201361. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-1486.","journal-title":"Cancer Res"},{"key":"8292_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1756-9966-31-26","volume":"31","author":"F Shojaei","year":"2012","unstructured":"Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, et al. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res. 2012;31:26. https:\/\/doi.org\/10.1186\/1756-9966-31-26.","journal-title":"J Exp Clin Cancer Res"},{"key":"8292_CR33","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1186\/s12967-024-05613-w","volume":"22","author":"W Tong","year":"2024","unstructured":"Tong W, Wang T, Bai Y, Yang X, Han P, Zhu L, Zhang Y, Shen Z. Spatial transcriptomics reveals tumor derived SPP1 induces fibroblast chemotaxis and activation in the hepatocellular carcinoma microenvironment. J Transl Med. 2024;22:840. https:\/\/doi.org\/10.1186\/s12967-024-05613-w.","journal-title":"J Transl Med"},{"key":"8292_CR34","doi-asserted-by":"publisher","first-page":"113944","DOI":"10.1016\/j.intimp.2024.113944","volume":"147","author":"Z Huang","year":"2025","unstructured":"Huang Z, Li Y, Liu Q, Chen X, Lin W, Wu W, Chen Z, et al. SPP1-mediated M2 macrophage polarization shapes the tumor microenvironment and enhances prognosis and immunotherapy guidance in nasopharyngeal carcinoma. Intl Immunopharmacol. 2025;147:113944. https:\/\/doi.org\/10.1016\/j.intimp.2024.113944.","journal-title":"Intl Immunopharmacol"},{"issue":"8","key":"8292_CR35","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3390\/cancers15082250","volume":"15","author":"E Matsubara","year":"2023","unstructured":"Matsubara E, Yano H, Pan Cheng, Komohara Y, Fujiwara Y, Zhao S, et al. The Significance of SPP1 in Lung Cancers and Its Impact as a Marker for Protumor Tumor-Associated Macrophages. Cancers. 2023;15(8):2250. https:\/\/doi.org\/10.3390\/cancers15082250.","journal-title":"Cancers"},{"issue":"8","key":"8292_CR36","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.3390\/ijms23084247","volume":"23","author":"J Messex","year":"2022","unstructured":"Messex J, Byrd CJ, Thomas MU, Liou G-Y. Macrophages Cytokine Spp1 Increases Growth of Prostate Intraepithelial Neoplasia to Promote Prostate Tumor Progression. Int J Mol Sci. 2022;23(8):4247. https:\/\/doi.org\/10.3390\/ijms23084247.","journal-title":"Int J Mol Sci"},{"key":"8292_CR37","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00405-017-4827-x","volume":"275","author":"HM Qin","year":"2018","unstructured":"Qin HM, Wang R, Wei GJ, Wang HF, Pan GG, Hu RT, et al. Overexpression of osteopontin promotes cell proliferation and migration in human nasopharyngeal carcinoma and is associated with poor prognosis. Eur Arch Otorhinolaryngol. 2018;275:525\u201334. https:\/\/doi.org\/10.1007\/s00405-017-4827-x.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"8292_CR38","doi-asserted-by":"publisher","first-page":"22239","DOI":"10.18632\/oncotarget.4161","volume":"6","author":"J Lin","year":"2015","unstructured":"Lin J, Myers AL, Wang ZW, Nancarrow DJ, Ferrer-Torres D, Handlogten A, et al. Osteopontin (OPN\/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget. 2015;6:22239\u201357. https:\/\/doi.org\/10.18632\/oncotarget.4161.","journal-title":"Oncotarget"},{"key":"8292_CR39","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4143\/crt.2016.572","volume":"50","author":"J Guo","year":"2018","unstructured":"Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C, et al. Ferroptosis: a novel antitumor action for cisplatin. Cancer Res Treat. 2018;50:445\u201360. https:\/\/doi.org\/10.4143\/crt.2016.572.","journal-title":"Cancer Res Treat"},{"key":"8292_CR40","doi-asserted-by":"publisher","first-page":"1288137","DOI":"10.3389\/fimmu.2023.1288137","volume":"14","author":"J Xing","year":"2024","unstructured":"Xing J, Cai H, Lin Z, Zhao L, Xu H, Song Y, et al. Examining the function of macrophage oxidative stress response and immune system in glioblastoma multiforme through analysis of single-cell transcriptomics. Front Immunol. 2024;14:1288137. https:\/\/doi.org\/10.3389\/fimmu.2023.1288137.","journal-title":"Front Immunol"},{"key":"8292_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12885-016-3024-4","volume":"17","author":"B Polat","year":"2017","unstructured":"Polat B, Kaiser P, Wohlleben G, Gehrke T, Scherzad A, Scheich M, et al. Perioperative changes in osteopontin and TGFbeta1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer. BMC Cancer. 2017;17:6. https:\/\/doi.org\/10.1186\/s12885-016-3024-4.","journal-title":"BMC Cancer"},{"issue":"10","key":"8292_CR42","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(05)70292-8","volume":"6","author":"J Overgaard","year":"2005","unstructured":"Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 2005;6(10):757\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(05)70292-8.","journal-title":"Lancet Oncol"},{"issue":"6","key":"8292_CR43","doi-asserted-by":"publisher","first-page":"100215","DOI":"10.1016\/j.mocell.2025.100215","volume":"48","author":"S Jung","year":"2025","unstructured":"Jung S, Ha J, Park JH, Yoo KH. Decoding SPP1 regulation: Genetic and nongenetic insights into its role in disease progression. Mol Cell. 2025;48(6):100215. https:\/\/doi.org\/10.1016\/j.mocell.2025.100215.","journal-title":"Mol Cell"},{"issue":"3","key":"8292_CR44","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s13365-019-00729-y","volume":"25","author":"M Calvez","year":"2019","unstructured":"Calvez M, Hseeh G, Benzer S, Brown AM. Osteopontin counters human immunodeficiency virus type 1-induced impairment of neurite growth through mammalian target of rapamycin and beta\u2010integrin signaling pathways. J Neurovirol. 2019;25(3):384\u201396. https:\/\/doi.org\/10.1007\/s13365-019-00729-y.","journal-title":"J Neurovirol"},{"issue":"14","key":"8292_CR45","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1158\/1078-0432.CCR-11-1952","volume":"18","author":"J Eswaran","year":"2012","unstructured":"Eswaran J, Li D-Q, Shah A, Kumar R. Molecular Pathways: Targeting P21-activated Kinase 1 Signaling in Cancer: Opportunities, Challenges and Limitations. Clin Cancer Res. 2012;18(14):3743\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1952.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"8292_CR46","doi-asserted-by":"publisher","first-page":"818","DOI":"10.21037\/jgo-24-302","volume":"15","author":"J Sun","year":"2024","unstructured":"Sun J, Tang M, Cai Z. SPP1 promotes tumor progression in esophageal carcinoma by activating focal adhesion pathway. J Gastrointest Oncol. 2024;15(3):818\u201328. https:\/\/doi.org\/10.21037\/jgo-24-302.","journal-title":"J Gastrointest Oncol"},{"key":"8292_CR47","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13046-024-03255-w","volume":"43","author":"C Liu","year":"2024","unstructured":"Liu C, Wu K, Li C, Zhang Z, Zhai P, Guo H, Zhang J. SPP1\u2009+\u2009macrophages promote head and neck squamous cell carcinoma progression by secreting TNF-\u03b1 and IL-1\u03b2. J Exp Clin Cancer Res. 2024;43:332. https:\/\/doi.org\/10.1186\/s13046-024-03255-w.","journal-title":"J Exp Clin Cancer Res"},{"key":"8292_CR48","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1038\/s41467-025-59529-0","volume":"16","author":"R Trehan","year":"2025","unstructured":"Trehan R, Huang P, Zhu XB, Wang X, Soliman M, Strepay D, et al. SPP1\u2009+\u2009macrophages cause exhaustion of tumor-specific T cells in liver metastases. Nat Commun. 2025;16:4242. https:\/\/doi.org\/10.1038\/s41467-025-59529-0.","journal-title":"Nat Commun"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08292-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08292-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08292-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:02:03Z","timestamp":1784566923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08292-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8292"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08292-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.05.28.656679","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies described herein were performed following approval by, and in accordance with the rules of the University of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee (Study protocol No. 00001499-RN03). Human archival primary and metastatic tumor tissues from patients diagnosed with oropharyngeal squamous cell carcinoma were used in this study. All samples were collected in accordance with the principles of the Declaration of Helsinki. The study was reviewed and approved by the Baylor College of Medicine Institutional Review Board (study No. H-40168). Written informed consent granted by Baylor College of Medicine Institutional Review Board was obtained from all participating patients.","order":1,"name":"Ethics","label":"<b>Ethics approval and consent to participate<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"926"}}